FDA approval of supplemental NDA for for Iclusig (ponatinb) in adult patients with newly diagnosed Ph+ ALL – Takeda
Takeda announced that the FDA has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute… read more.
